Haploidentical Hematopoietic Stem Cell Transplantation

Status Active, not recruiting

Clinical Trial Summary

The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.

Clinical Trial Description

Research subjects will undergo reduced intensity conditioning (Hydroxyurea, ATG, Fludarabine, Thiotepa, Melphalan) followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year The use of the CliniMACS device for CD34 selection will be performed at CNMC through cross-reference of the master file for CliniMACS CD34+ Reagent by Milteyni Biotech (BB-MF 8061). CliniMACs is an electromechanical device intended to isolate certain cell subsets from mixed cell populations. When used in combination with the CliniMACs CD34 reagent, it is possible to prepare extremely pure populations of CD34+ cells with upwards of 5 logs depletion of contaminating T cells within a closed and sterile system. We intend to use this system to select cells from HLA haploidentical related donors who have been mobilized with G-CSF prior to stem cell collection. Since previous investigations of this strategy in adult patients have not translated into enhanced long term survival, we intend to limit this protocol to patients under the age of 22 as they have more rapid immune reconstitution. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02165007
Study type	Interventional
Source	Children's National Research Institute
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	January 2015
Completion date	March 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT04614779` - Long-term Clinical Study of CN128 in Thalassemia Patients	Phase 2
Completed	`NCT01158794` - Genes Influencing Iron Overload State
Recruiting	`NCT02995707` - The Effective and Safety of Thalidomide in NTDT	Phase 2
Active, not recruiting	`NCT01935661` - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00901199` - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload	Phase 2
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Recruiting	`NCT05508932` - Atrial Fibrillation in Beta-Thalassemia
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT03095326` - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia	Phase 4
Completed	`NCT03117192` - Zinc Supplementation on Cellular Immunity in Thalassemia Major	Phase 4
Completed	`NCT01443312` - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed	`NCT00744692` - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders	Phase 1
Completed	`NCT00235391` - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload	Phase 3
Not yet recruiting	`NCT06058260` - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed	`NCT05529550` - Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Completed	`NCT04582110` - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting	`NCT06213402` - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)